Adieu to Aduhelm: Biogen Stops Marketing Antibody
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
6404 RESULTS
Sort By:
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
Among 1,092 people with PCA, symptoms started around age 60, and 94 percent had amyloid plaques or neurofibrillary tangles.
The α-helical chains of two ApoEs wrap around lipoprotein discs. They circle in opposite directions.
Eight adults who, as children, had received growth hormone from cadavers developed cognitive problems and/or AD-like pathology in midlife.
Risk variant promotes TMEM106b fibrillization; protective variant discourages it.
The patient, an APOE4 homozygote with severe cerebral amyloid angiopathy, developed vascular inflammation and bleeding throughout her brain.
With several thousand people across the U.S. on the drug, wait times are long, and clinics are hiring. How to meet growing demand?
Scientists around the globe are studying how best to deploy Alzheimer's plasma tests in the real world. Their focus: primary care.
ALZpath’s assay detected an annual rise in plasma phospho-tau217 in amyloid-positive people, with the steepest increase in those who also have tangles.
The enzyme cholesterol 24-hydroxylase protected against cognitive decline and tau pathology—but only in females.
The software could improve prognosis, speed referrals, for people with MCI, the developer claims.
When LOAD2 mice, which carry Alzheimer’s risk variants, eat a fatty diet, their proteomes change, their neurons die, and their memories fail. All sans amyloid plaques.
The biomarker may signal tau’s early days of entanglement, and serve as a useful disease staging indicator, according to a new immunoassay.
Growth-associated protein 43 in the CSF identified people who accumulated tangles fastest. These spread through connected brain regions.
Last summer saw a first: the traditional approval of a disease-modifying Alzheimer's therapy. Solid progress on biomarkers, and a flourishing of basic research, made for a good year.